BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX) announced that CEO Lance Alstodt was interviewed on "The Big Biz Show" on October 7, 2025. The interview covered BioRestorative’s recent clinical and regulatory milestones and highlighted commercial opportunities the company is pursuing.

The interview is being or will be broadcast on cable TV and streaming platforms including Roku, and on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media across 175 countries. Podcasts are available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, and to subscribers of biztv.com and ytaclub.com.

MELVILLE, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today is pleased to announce that its CEO, Lance Alstodt, participated in an interview with “The Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show.

During the interview, Mr. Alstodt discussed BioRestorative’s recent achievements of key clinical and regulatory milestones, as well as highlighted some of the significant commercial opportunities that the Company is pursuing.

The interview has or will be aired on cable TV and streaming services, including Roku, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media in 175 countries.

To access the full interview please click here.

Podcasts of the show are available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, as well as to subscribers of biztv.com or ytaclub.com.

About The Big Biz Show

Widely regarded as "Business with a Bite," The Big Biz Show is an Emmy Award-winning nationally syndicated radio and TV program. The fast-talking, hard-hitting show is hosted by Bob "Sully" Sullivan, who is also a weekly contributor on the FOX Business Network. For more information, go to www.bigbizshow.com.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem^®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com

FAQ

When did BioRestorative CEO Lance Alstodt appear on The Big Biz Show about BRTX?

The interview was announced on October 7, 2025 and features CEO Lance Alstodt discussing company milestones.

What topics did Lance Alstodt discuss about BRTX on The Big Biz Show?

He discussed BioRestorative’s recent clinical and regulatory milestones and the commercial opportunities the company is pursuing.

Which platforms will carry the BRTX interview with Lance Alstodt?

The interview will air on cable TV and streaming including Roku, plus radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media.

How widely is the BRTX interview being distributed internationally?

The radio and TV distribution covers 175 countries through the listed networks and streaming partners.

Where can investors listen to the BioRestorative interview podcast for BRTX?

Podcasts are available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, and to subscribers of biztv.com and ytaclub.com.

Does the BRTX interview include discussion of specific clinical trial results or dates?

The interview references recent clinical and regulatory milestones, but no specific trial results, figures, or dates were provided in the announcement.